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Abstract
Hypertension and diabetes mellitus are closely interrelated and coexist in as many as two-thirds of
patients with type 2 diabetes. The consequent risk of such an association is an accelerated
development of atherosclerotic cardiovascular disease and nephropathy complications.
In choosing an antihypertensive agent, effectiveness needs to be accompanied by favourable
metabolic, cardioprotective, and nephroprotective properties. Given the multifactorial nature of
hypertension, the approach that has gained widespread agreement is treatment with more than one
agent. Agents with different mechanisms of action increase antihypertensive efficacy because of
synergistic impacts on the cardiovascular system. Combination therapy allows the use of lower
doses of each antihypertensive agent which accounts for the excellent tolerability of combination
products.
The aim of the present study is to quantify the efficacy of combination therapy of Eprosartan 600
mg respectively Ramipril 5 mg with low-dose Hydrochlorothiazide and Moxonidine on blood
pressure levels in patients with essential hypertension and associated diabetes mellitus type 2.
The use of monotherapy (Eprosartan or Ramipril) followed by addition of low-dose
Hydrochlorothiazide as second agent and of Moxonidine as a third agent will be individualized to
the severity of hypertension in the particular patient and to his/her degree of response to current
treatment.
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Background
The clinical combination of hypertension and diabetes
carries a particular poor prognosis [1-6]. Clinical studies
done in individuals with type 2 diabetes and substudies
obtained from clinical trials done in the general popula-
tion have demonstrated that achievement of goal blood
pressure (< 130/80 mm Hg) in this patient category is cru-
cial in decreasing the premature morbidity and mortality
[7]. Thus, management of subjects with type 2 diabetes
and associated hypertension needs to be early and aggres-
sive, and must use a global approach. Findings from large,
international outcomes studies as well as guidelines and
recommendation of prestigious international scientific
bodies have made available consensus recommendations
[8-13].
The challenge clinicians are facing is to tighten blood pres-
sure control to less than 130/80 mmHg and to adjust ini-
tiation of therapy to the severity of hypertension in the
individual patient.
This multicenter study will evaluate the efficacy and toler-
ability of monotherapy, double- and triple- antihyperten-
sive combination therapies in a large spectrum of
hypertension & diabetes patient population, as summa-
rised in Table 1.
Table 2 (see Additional file 1) specifies the treatment strat-
egies to be employed in the study as adjusted to severity of
hypertension in the particular patient and to his/her
degree of response to that therapy.
The primary objectives of hypertension management in
patients with diabetes are to reduce blood pressure levels
to currently recommended target level and thus to reduce
the risk of cardiovascular and renal complications without
adversely impacting glycemic and lipid control.
Previous debate regarding the level of blood pressure
reduction that optimizes cardiovascular risk reduction is
currently settled. BP goal of < 130/85 mmHg promoted by
the JNC-VI guidelines issued 1997 [10] were replaced in
2002 by a position paper of the American Diabetes Asso-
ciation (ADA) supporting a target blood pressure in
hypertension & diabetes patients of < 130/80 mmHg [14].
This blood pressure-goal is also endorsed by the most
recent JNC-7 guidelines [15] and two other American pro-
fessional societies [16,17] as well as by the ESH/ESC [9]
and formally by the ISH.
A widespread agreement, supported by the above men-
tioned organizations/societies is in place, regarding the
principles governing the use of appropriate antihyperten-
sive drug combinations to maximize hypotensive efficacy
while minimizing side effects. Polypharmacy is common
place and, with at least one third of patients requiring two
or more agents simultaneously, a paradigm shift in the
approach of initiating therapy is done by advocating use
of two agents in subjects with more severe hypertension
(BP in excess of 20/10 mmHg above goal). Low-dose thi-
azide diuretic is favored as one of the two starting agents.
In general, monotherapy is likely to be successful in mild
hypertensive patients (grade 1 hypertension) without
associated major risk factors for CHD. In contrast, patients
with type 2 diabetes need more rigorous control of BP in
an easier, simpler fashion, given the remarkable complex-
ity of the multiple drug regimens needed to control their
comorbid medical problems (e.g., diabetes, obesity, high
cholesterol).
A large body of evidence derived from a multitude of
international trials have demonstrated both the benefit of
low-level, goal blood pressure, in terms of prevention of
long-term complications and, the need for multiple drug
combinations in order to achieve that goal [13,18-20].
Furthermore, in a computer-modelled cost-effectiveness
analysis of the JNC-VI treatment goal (< 130/85 mmHg),
lowering blood pressure to goal increases patients' life
expectancy and decreases long-term cost [21]. Cost-effec-
tiveness analysis in the context of the UKPDS study has
also revealed that incremental cost of tight control
(< 150.85 mmHg) versus less tight control (< 180/105
mmHg) was considered to be effective [22].
In the HOT study [13], which recruited grade 2 and 3
hypertensives after washout from previous agents, mono-
therapy was successful in only 25–40% of patients,
according to the target diastolic blood pressure. In trials of
diabetic patients, the vast majority were on at least two
Table 1: Large spectrum of hypertension and diabetes patient population selected for the multicenter study that will evaluate the 
efficacy and tolerability of monotherapy and double and triple-antlhy pertensive combination therapies
GoalBP* Threshold Upper limit
for all patients regardless BP values for initiation of double-combination of BP values targeted
< 130/80 mmHg > 150/90 mmHg ≤ 179/109 mmHg
* The Goal BP defines the cut off point for responders/non-responders to any therapy.Current Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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drugs, and, in two recent trials on diabetic nephropathy
[23,24] an average of 2.5 to 3.0 non-study drugs were
required in addition to the angiotensin receptor antago-
nist used in these studies (losartan/irbesartan).
Given the very poor BP control rate, i.e., 11% in patients
with hypertension & diabetes, the use of combination
therapy is an important therapeutic consideration, as it
facilitates quicker and easier attainment of goal BP and
should lead to a greater proportion of people with diabe-
tes who achieve BP goal. Initiation of treatment by combi-
nation therapy was effectively tested in the VA study at the
beginning of the antihypertensive treatment trial era
[25,26] and recently in the PROGRESS study [27].
Methods
Patient Population
Subjects will be recruited in outpatient clinics/offices of
general practitioners and internal medicine/cardiology
specialists from the entire spectrum of patients having
coexistent hypertension and diabetes mellitus type 2. The
upper limit of blood pressure values targeted (≤ 179/109
mmHg) correspond grade 2 hypertension (according to
current ESC/ISH and WHO guidelines).
Subjects to be recruited are supposed to have both entities
(hypertension with BP values in the range ≥ 130/80 – ≤
179/109 mmHg and diabetes mellitus type 2) diagnosed
since previously, undergoing current antihypertensive
treatment and, to be eligible for the study according to the
specific inclusion/exclusion criteria described below.
The study consists of five distinct phases: Screening (S)
(up to seven days), Placebo Run-in phase (two weeks),
monotherapy (four weeks, double-blind fashion), dou-
ble-combination treatment (Eprosartan/HCTZ respec-
tively Ramipril/HCTZ for four weeks, HCTZ open
labelled), triple-combination treatment (Eprosartan/
HCTZ/Moxonidine versus Ramipril/HCTZ/Moxonidine
with HCTZ and Moxonidine open labelled) and Follow-
up (two to seven days). Patients allocated to monotherapy
will participate in the study for a four weeks period while
those starting with double combination therapy will
receive medication for a maximum of 12 weeks.
The flowchart below captures the main events during the
study conduct (Fig. 1).
Randomization and Blinding
Randomization will be concealed.
A stratified randomization will be employed based on the
following rules:
1. Subjects with blood pressure in range: BP ≥ 130/80 – ≤
150/90 mm Hg will be randomly allocated to one of the
monotherapy arms (Eprosartan or Ramipril). 30 subjects
will be recruited for each arm.
2. Subjects with blood pressure in the range: BP > 150/90
– ≤ 179/109 mm Hg will be randomly allocated to dou-
ble-combination therapy (Eprosartan/HCTZ or Ramipril/
HCTZ); 190 subjects will be recruited for each arm.
The randomization lists will be provided by the Depart-
ment of Clinical Supplies at Solvay Pharmaceuticals BV
with the program ADLS. Patients will be allocated in equal
numbers to each sequence. A fixed block size of patients
will be used, and only complete blocks of study medica-
tion will be provided to the centers.
Within each center, randomization numbers will be used
in ascending order and patients will be allocated to rand-
omization code numbers in chronological order. The
study will be unblinded when all CRFs are in house and
the data on the database have been declared clean.
The following drugs are to be used in the study:
• Eprosartan 600 mg, once daily
• Ramipril 5 mg, once daily
• Hydrochlorothiazide 12.5 mg, once daily
• Moxonidine 0.4 mg, once daily
• Placebo tablets matching Eprosartan 600 mg and Rami-
pril 5 mg will be used in the monotherapy, in the double-
and in the triple-combination therapy phases. Hydrochlo-
rothiazide tablets will be open labelled in the double- and
triple-combination therapy phases. Moxonidine tablets
will open-labelled in the triple-combination therapy
phase.
Eprosartan and Ramipril and the corresponding placebos
will be packaged according to the double-dummy tech-
nique. Fig. 2 summarizes the treatment algorithm.
Monotherapy (Eprosartan vs. Ramipril)
Patients eligible for participation in the study by the
assessment at V2 will be randomized on the basis of the
severity of their hypertension and allocated to either mon-
otherapy or to double-combination therapy (described
below).
Patients with initial blood pressure values in the range
≥ 130/80 – ≤ 150/90 mmHg, will be randomly allocated
to one of the monotherapy groups.Current Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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By the end of the first four-week phase an assessment will
be made as to whether patients have reached or not the
"goal" hypertension (< 130/80 mmHg).
Patients on monotherapy deemed to be responders at the
end of four weeks treatment (i.e., have reached the "goal")
will terminate their participation in the study and be fol-
lowed up during the ensuing two to seven days after
stopped monotherapy (procedure similar with Follow-up
at end of study (V6).
Non-responders (according to above mentioned criteria,
i. e., with BP still ≥ 130/80 mmHg), will receive double-
combination therapy (Eprosartan/HCTZ respectively
Ramipril/HCTZ) and will be followed-up for eight weeks
(red-dotted line in the flowchart).
Double-combination Therapy (Eprosartan/HCTZ vs. 
Ramipril/HCTZ)
Patients with initial blood pressure values in the range >
150/90 – ≤ 179/109 mmHg, will be randomly allocated to
double-combination therapy. By the end of this first four-
week phase an assessment will be made as to whether
patients have reached or not the "goal" hypertension (<
130/80 mmHg).
Responders  will maintain double-combination therapy
and will be followed-up for an eight week period (V3
toV5, dotted-line in the flowchart) and retain therapy
unchanged.
Non-responders  will receive triple-combination, as
described below.
Study Design Figure 1
Study Design. A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan ver-
sus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with essential hyperten-
sion and associated diabetes mellitus type 2.
Eprosartan 600 mg*
Ramipril 5 mg**
Eprosartan 600 mg* + HCTZ 12.5 mg
Ramipril 5mg** + HCTZ 12.5 mg
2 weeks 4 weeks 8 weeks 2 – 7 days
Screening Placebo Run-in   Mono- or double- Combination therapy with two, respectively Follow-up
combination therapy adjusted  three agents in non-responders of the four initial arms
to severity of hypertension
V0 V1 V2 V3 V4 V5 V6
S – Screening, R – Randomization, V0 – V6± 5 days – scheduled visits, HCTZ – Hydrochlorothiazide,
-switch of non-responders to double-combination therapy,   - switch of non-responders to triple-combination therapy,
*- + Placebo matching Ramipril, **- + Placebo matching Eprosartan (packaging by double-dummy technique)
Eprosartan 600 mg* + HCTZ 12.5 mg + Moxonidine 0.4 mg
R
Ramipril 5 mg** + HCTZ 12.5 mg + Moxonidine 0.4 mgCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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Triple-combination Therapy (Eprosartan/HCTZ/
Moxonidine vs. Ramipril/HCTZ/Moxonidine)
Non-responder patients after four weeks of double-combi-
nation therapy will receive triple-combination (Eprosar-
tan/HCTZ/Moxonidine vs. Ramipril/HCTZ/Moxonidine)
and will be followed-up for an eight weeks period (V3 to
V5).
After the first four weeks of monotherapy respectively
double-combination therapy (V3), patients will be reas-
sessed for compliance, adverse events and supplied with
medication for the next eight weeks (except for the mon-
otherapy patients who reached goal blood pressure and
who will terminate the study).
During the eight weeks triple-combination therapy all
patients will be reassessed for compliance and adverse
events (visits V4, V5 and V6). A 12-lead ECG will be per-
formed by S, V3 and V5 while safety laboratory parame-
ters will be performed by S, V2 and finally by visit V5.
A Follow-up Visit will be performed on all patients with
full physical examination, BP and pulse rate check within
the ensuing two to seven days after study end (V6). Fur-
ther follow-up and optimal treatment will be decided on
a case-by-case basis by the physician in charge. Table 3
(see Additional file 2) displays a summary of the sched-
uled investigations, as planned for each particular visit.
Inclusion Criteria
1. Males and females aged 40 to 80 years of age. Women
of childbearing age will be subject to pregnancy testing
and will agree to maintain adequate hormonal
contraception.
Treatment Algorithm Figure 2
Treatment Algorithm
BP ≥ 130/80 - ≤ 150/90
BP > 150/90 - ≤ 179/109
Monotherapy*
Eprosartan 600 vs. Ramipril 5
Double-combination therapy*
Eprosartan/HCTZ 600/12.5
vs. 
Ramipril/HCTZ 5/12.5
Hypertension
+ 
DM type 2
Double-combination therapy*
Eprosartan/HCTZ 600/12.5
vs. 
Ramipril/HCTZ 5/12.5
Triple-combination therapy*
Epro./HCTZ/Moxo 600/12.5/0.4
vs.
Ramipril/HCT/Moxo 5/12.5/0.4
Finish study
Responders (BP < 130/80)
Non-responders (BP ≥ 130/80)
Responders (BP < 130/80)
Non-responders (BP≥ 130/80)
Screening                          Placebo                Mono- or double-combination therapy                                              Combination therapy with two-, 
adjusted to severity of hypertension              respectively three agents in non-responders
of the four initial arms
1 week                              2 weeks                    4 weeks                                      8  weeks
R
* - Eprosartan and Ramipril to be administered together with corresponding placebo (double-dummy technique).Current Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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2. Eligible patients should have diagnosed essential
hypertension (not controlled with current treatment, i.e.,
BP ≥ 130/80 – ≤ 179/109 mmHg) and diagnosed associ-
ated diabetes mellitus type 2, willing to accept withdrawal
of any antihypertensive medication by the time of the
Screening visit.
Exclusion Criteria
A multitude of exclusion criteria, carefully listed in the
study protocol, can be summarised in three different
groups:
1. Ineligibility based on hypertension grade 3 (BP ≥ 180/
110 mmHg), any form of secondary hypertension or
hypotension (SBP ≤ 90 mmHg).
2. Any form of organic heart disease requiring medical
treatment that might have hypotensive effect, imply need
for invasive investigation or surgery.
3. The patient is suffering from a severe concomitant ill-
ness related to any body organ or system, likely to affect
outcome assessment. Likewise, ineligibility is declared for
patient anticipated to have compliance problems, partici-
pants in another trial during the past 30 days, pregnancy
and lactations and known hypersensitivity to ingredients
of any of the employed agents (eprosartan, ramipril,
hydrochlorothiazide, moxonidine). In addition, diabetes
mellitus type 1 is exclusion criteria.
Study Outcomes
Prior and Concomitant Therapy
The study protocol calls for every patient to be treated
optimally by the physician in charge and to receive com-
prehensive, individualized lifestyle change advice regarding
relevant diet and physical activity. Visits are to be sched-
uled in the context of the study (at four weeks interval dur-
ing ongoing treatment). Any antihypertensive medication
should be withdrawn latest by Screening visit and will be
prohibited during the whole period of ongoing study.
Ethics and Informed Consent
The study will be conducted in accordance with ICH GCP
and the European Directive 2001/20/EC of the European
Parliament and of the Council of 4 April 2001 (on the
approximation of the laws, regulations and administrative
provisions of the member states relating to implementa-
tion of good clinical practice in the conduct of clinical tri-
als of medicinal products for human use) and on the basis
of ethical principles laid down in the current revision of
the Declaration of Helsinki (Edinburgh 2000). In addi-
tion, Solvay Pharmaceuticals GmbH policies and proce-
dures should also be followed.
Written consent, involving provision of detailed informa-
tion regarding the study objectives, design, scope of the
intervention, risks and benefits, will be obtained for all
patients before initiating any study procedures. Likewise,
study documentation is to be subject to the scrutiny of
local ethical committees in the two countries participating
in the study.
Sample Size and Statistical Analysis
Efficacy
The primary objective is to demonstrate the superiority of
combination therapy of Eprosartan/HCTZ (600/12.5 mg)
versus Ramipril/HCTZ (5/12.5 mg) with the primary
parameter of attention being the percentage of patients
brought to goal blood pressure (<130/80 mmHg) at visit
V3.
Null hypothesis: H0: PE+HCTZ = PR+HCTZ
Alternative hypothesis: H1: PE+HCTZ ≠ PR+HCTZ,
Where PE+HCTZ is the percentage of patients brought to
goal blood pressure at visit 3 with Eprosartan/HCTZ and
PR+HCTZ is the percentage of patients brought to goal blood
pressure at visit V3 with Ramipril/HCTZ.
The primary parameter will be analyzed using the
Cochran-Mantel-Haenszel test, controlling for center
effects. Statistical significance will be assessed with a two-
sided test at 0.05 α level. The confirmative analysis of the
primary parameter will be performed on the intent-to-
treat patient sample.
Secondary efficacy objectives:
• To compare the mean change in sitting systolic blood
pressure (sitSBP) and sitting diastolic blood pressure (sit-
DBP) between Eprosartan/HCTZ and Ramipril/HCTZ (V3
vs. V2).
• To compare the percentage of patients brought to goal
blood pressure by the triple-combination Eprosartan/
HCTZ/Moxonidine vs. Ramipril/HCTZ/Moxonidine (V5
vs. V3).
• To compare the mean change in sitSBP and sitDBP
between triple-combination with Eprosartan/HCTZ/Mox-
onidine vs. Ramipril/HCTZ/Moxonidine (V5 vs. V3).
• To compare the mean change in sitSBP and sitDBP
between monotherapy with Eprosartan vs. Ramipril (V3
vs. V2)
• To compare the percentage of patients brought to goal
blood pressure at visit V5 between Eprosartan/HCTZ andCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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Ramipril/HCTZ in patients not at goal blood pressure
after four weeks of monotherapy.
• To compare the mean change in sitSBP and sitDBP as
well as the responder rate in patients non-responders (not
at goal) after four weeks of monotherapy (switched to
double combination therapy) (V5 vs.V3); and to compare
the mean change in sitSBP and sitDBP as well as the
responder rate maintenance in patients who reached goal
blood pressure value at the end of first four weeks of dou-
ble-combination therapy and successively entered an
eight weeks follow-up period (V5 vs.V3).
Changes in blood pressure parameters will be assessed by
analysis of covariance (ANCOVA). The model will include
the intercept, treatment and center as fixed effects and the
baseline value as covariate. For response rates, the treat-
ment groups will be compared using the Cochran-Mantel-
Haenszel test, controlling for center effects. Comparisons
of the medication regimens will be reported along with
95% confidence intervals of the relative risk ratios. These
analyses will be considered as exploratory.
Safety
All patients who receive at least one dose of double-blind
medication will be assessed for clinical safety and tolera-
bility. Evaluation of safety data will be based on compar-
isons of patient experience by treatment group. Clinical
interpretation of safety will be based on reviews of stand-
ard displays of adverse events incidence, pulse rate data,
and laboratory test values. Summary statistics of labora-
tory test values and incidence of adverse events according
to treatment and time of onset will be presented.
Sample Size, Power and Level of Significance
A formal sample size estimation has been done for
patients with blood pressure in the range: > 150/90
mmHg and ≤ 179/109 mmHg.
Assuming that 55% of the patients in the Eprosartan/
HCTZ group would reach goal  blood pressure as com-
pared with only 40% in the Ramipril/HCTZ group, a
0.05% two-sided significance level with 80% power to
detect the targeted 15% difference will imply the need for
346 patients supposed to complete the four-weeks dou-
ble-combination therapy phase. Further 35 patients (10%
of the total) will be recruited to account for drop-outs.
In addition, 60 subjects with BP ≥ 130/80 and ≤ 150/90
mmHg will be randomly allocated to either Eprosartan or
Ramipril monotherapy group at visit V2. Inclusion of
monotherapy phase with a relatively low number of
patients (30 subjects per arm) is justified by the intention
to therapeutically target the whole spectrum of patient
population having coexistent diabetes mellitus type 2 and
mild to moderate hypertension, in whom the agents
tested are likely to be effective.
Blood Pressure Measurements
Office blood pressure will be determined by Riva-Rocci
method with a mercury or a mercury calibrated sphyg-
momanometer throughout the study. All measurements
will be made on the same arm supported at heart level,
using the same cuff size and the same equipment. If the
patient's arm circumference is > 32 cm, a large blood pres-
sure cuff should be used. Diastolic blood pressure will be
measured at the disappearance of Korotkoff sounds pha-
seV. Measurements should be taken by the same staff
member at the particular visits.
For an individual patient blood pressure measurements
should be performed at 24 hours after the last oral dose,
at the same time (± 2 hour) in the morning, between 8
and 10 am. Blood pressure will be measured in the follow-
ing sequence: after the patient sits quietly for at least 5
minutes, blood pressure will be measured twice at approx-
imately 2-minutes interval. The average of these measure-
ments will be recorded. If the difference between
measurements is in excess of 5 mmHg a third reading will
be performed and the average value recorded as mean sit-
ting systolic and diastolic blood pressure.
Measurements should be performed by the same study
assistant using the same device, in each of the centres
involved in the study.
Discussion
The current evidence base is strongly in favour of combin-
ing drugs in order to achieve blood pressure goals, in par-
ticular in patients with coexistent hypertension &
diabetes. Likewise, there is a widespread agreement in the
scientific community as to the goal blood pressure to be
achieved in these patients. Further, common sense in clin-
ical practice dictates that combination therapies should be
tailored to severity of hypertension in the individual
patient and that, eventual associated risk factors/comor-
bidities should be accounted for in the process of treat-
ment decision making.
Patients with high blood pressure and associated
impaired glucose tolerance or overt diabetes mellitus type
2, as a group, are insulin resistant, [28] glucose intolerant
[29-31], hyperinsulinemic [32-36], dyslipidemic [37-42]
and with evidence of endothelial dysfunction [43,44].
Extensive epidemiological evidence indicates that diabetic
individuals with hypertension have greatly increased risk
of cardiovascular disease, renal insufficiency, and diabetic
retinopathy [45-47].Current Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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For every 5 to 10 mmHg decrease in systolic blood pres-
sure achieved with diuretics, ARBs, ACE inhibitors, beta-
blockers or calcium channel blockers in patients with dia-
betes, there is a 20% to 30% relative risk reduction in car-
diovascular events [48-53].
Agents belonging to the nine, most well-known different
antihypertensive drug classes produce a similar reduction
in systolic and diastolic blood pressure (10–15 and 5–10
mm Hg respectively). Differences in terms of magnitude
of blood pressure lowering, as indicated by results from
comparative efficacy studies, are usually small [54]. How-
ever, larger differences have been shown as to effects on
hard endpoints (myocardial infarction, heart failure,
stroke).
Comparisons between different agents in patients with
hypertension & diabetes mellitus type 2, convincingly
point to ACE inhibitors and ARBs as being the two classes
of antihypertensive drugs that reduce the activity of the
renin-angiotensin II system, and should be among the
preferred first-step drugs for the treatment of these condi-
tions [55]. Angiotensin II increases blood pressure by
enhancing aldosterone synthesis, resulting in sodium
retention and direct vasoconstriction. The first step in this
pathway is inhibited by adrenergic blockers. The third and
forth steps are inhibited by ACE inhibitors and ARBs,
respectively [56].
Clinical trials carried out world-wide have shown that
ACE inhibitors have renoprotective effects [57,58] and
clear cardiovascular benefits [59-63]. Their main side
effects are dry cough and angioedema.
In contrast, in placebo-controlled trials, the ARBs have
demonstrated almost no side effects [64]. Both ACE inhib-
itors and ARBs have been shown to maintain quality of
life of hypertensive patients equal to or better than other
classes of antihypertensive drugs [65-68]. The only labora-
tory abnormality that may occur with agents from both
classes is mild hyperkaliemia, especially in some elderly
patients with type 2 diabetes who have hyporeninemic-
hypoaldosteronism [69].
Use of low-dose thiazide diuretic (< 25 mg) as a second
agent in treatment of patients with hypertension & diabe-
tes is well-documented and widely recommended [21,70-
73]. It has beneficial effects on both morbidity and mor-
tality figures while, previous general concern on the nega-
tive impact of diuretics on the different lipid parameters is
no longer justified as, all long-term studies with low-dose
diuretics have not been shown to affect lipid profiles in a
negative way [74-76]. Moreover, in studies of a year or
more, diuretics have been shown to reduce cardiovascular
risk in every trial to date [77-79].
Since drug combinations may be required for many years
in the age-groups in which type 2 diabetes is most
prevalent, there have been calls for the use of agents
devoid of adverse effects on carbohydrate and lipid
metabolism. It has been suggested that such effects may
account for the shortfall in reduction of coronary heart
disease observed in clinical trials of diuretics and β-block-
ers [80,81].
Moxonidine stimulates imidazoline-I1  receptors in the
medulla, thereby reducing central sympathetic drive and
attenuating peripheral vascular resistance. In addition,
reduced sympathetic drive results in lower plasma con-
centrations of catecholamines and renin. Randomised
comparative studies show that the efficacy of moxonidine
as monotherapy is similar to that of other antihyperten-
sive agents [82]. Moreover, selectivity for the I1 receptor
greatly reduces the adverse affects attributable to costimu-
lation of medullary α2-adrenoceptors [82] observed with
the first generation of centrally acting agents, α-methyl-
dopa and clonidine.
In clinical studies, moxonidine has been shown to have
neutral or beneficial effects on lipid and carbohydrate
metabolism [82,83]. A retrospective analysis suggested
minor dose-dependent reductions in fasting plasma glu-
cose in moxonidine-treated hypertensive patients.
On the available evidence, moxonidine seems to be a log-
ical choice as component of combination treatment of
patients with hypertension and associated diabetes melli-
tus type 2 or impaired glucose tolerance.
Conclusions
The poor blood pressure control in patients with hyper-
tension & diabetes in everyday life lies, at least in part, in
the emphasis in the evidence-based guidelines of the
recent past towards advice on initial, single treatments as
well as in their lack of clarity and transparency in recom-
mending pre-specified blood pressure targets [10,84-86].
Previous consensual advice that combination treatments
expose patients to the increased risk of adverse events has
been replaced by good evidence to the contrary: use of sev-
eral agents combined or of fixed-dose combinations treat-
ments have the potential to bring patients to goal blood
pressure and thereby to minimize long term risk of hyper-
tension/diabetes-related complications [22-27,87].
Despite the apparent simplicity of the paradigm shift
towards clear blood pressure goal and individualized therapy
on the basis of hypertension severity (and addition of a third
agent in case of uncontrolled BP with two agents), com-
parative data to guide clinical practice is still lacking andCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:9 http://cvm.controlled-trials.com/content/5/1/9
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this applies also to the comparison of ARBs versus ACE
inhibitors. The present study attempts to explore this area.
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